// App-Quantinova.ai

15893 : Risk of Clinical Outcomes and Baseline Atrial Fibrillation: Irbesartan in Heart Failure With Preserved Ejection Fraction (I-PRESERVE) Trial

Researchers

Presenter

  • Sithu Win

Principal Investigators

  • Thomas Rector

  • Michel Komadja

  • Michael Zile

  • Robert McKelvie

  • John McMurray

  • Barry Massie

  • Peter Carson

  • Inderjit Anand

Medical Centers

  • Georgetown University, Washington, DC

  • McMaster University, Hamilton, ON, Canada

  • BHF Glasgow Cardiovascular Res Ctr, Glasgow, United Kingdom

  • VA Medical Center, Minneapolis, MN.

  • University of Minnesota, St. Paul, MN

  • VA Medical Center, Minneapolis, MN.

  • Rutledge St, Charleston, SC

  • APHP, Pitie-Salpetriere Hospital, paris, France

  • San Francisco VA Medical Center, San Francisco, CA

Locations

  • United States

  • Canada

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Heart failure with preserved ejection fraction

  • Left ventricular hypertrophy

  • Arrhythmia

  • Congestive heart failure

  • Stroke

Biomarkers

  • N-terminal pro b-type natriuretic peptide

Drug/Treatment

  • Irbesartan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved